-+ 0.00%
-+ 0.00%
-+ 0.00%

Estrella Immunopharma doses first patient in STARLIGHT-1 trial expansion for EB103 in relapsed B-cell NHL

PUBT·07/24/2026 12:01:25
Listen to the news
Estrella Immunopharma doses first patient in STARLIGHT-1 trial expansion for EB103 in relapsed B-cell NHL
  • Estrella Immunopharma dosed the first patient in the dose-expansion phase of its STARLIGHT-1 Phase I/II trial of EB103 in relapsed or refractory B-cell non-Hodgkin’s lymphoma.
  • Early results were already presented from the dose-escalation phase, showing responses that remained durable at a six-month assessment in evaluable patients without CNS involvement.
  • The expansion cohort aims to confirm safety and efficacy at the recommended Phase II dose to guide the pivotal-trial strategy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607240800BIZWIRE_USPR_____20260724_BW356360) on July 24, 2026, and is solely responsible for the information contained therein.